BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
10 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States
- Uc Irvine Health/chao Family Comprehensive Cancer Center
Orange, California, United States
- Yale University
New Haven, Connecticut, United States
- Mayo Clinic in Florida
Jacksonville, Florida, United States
- Northwestern University
Chicago, Illinois, United States
- Dartmouth Hitchcock Medical Center/dartmouth Cancer Center
Lebanon, New Hampshire, United States
- Wake Forest University at Clemmons
Clemmons, North Carolina, United States
- Wake Forest Baptist Health - Wilkes Medical Center
Wilkesboro, North Carolina, United States
- Wake Forest University Health Sciences
Winston-Salem, North Carolina, United States
- Vcu Massey Comprehensive Cancer Center
Richmond, Virginia, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 17 Feb 2021
- Primary completion
- 27 Nov 2024
- Completion
- 30 Jan 2027
- Last update posted
- 12 Jun 2026
- Registered enrollment
- 49
- Registry id
- NCT04214249
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.